Dr. Geraldine, PhD

God 1st. | STEM creative| Biochem/Molec Bio PhD | Dir. of Funding @VanguardSTEM | Equity Research @ Citizens/JMP tweets = my thoughts

[Dr. Geraldine, PhD @__GhD_]

Hey friends, I’m Geraldine Ezeka #BlackInCancerRollCall. I’m a 5th year PhD candidate @UMmedschool
identifying different molecular targets of sulforaphane, a nature derived anti-cancer agent, in mesothelioma.

[VanguardSTEM @VanguardSTEM]

5 Tips for Turning Your PhD Internship into a Full-Time Offer!
https://t.co/EH6iFDiQqD

[Dr. Geraldine, PhD @__GhD_]

hey STEMverse: during your PhD (or research experience), did you find that 1 of the limitations to your progress was 1) inadequate reagents (ex antibodies that sucked) 2) inadequate equipment (ex equipment didn’t do as suggested) or 3) improper protocol 4) or a mix of the above?

[Adam Feuerstein ✡️ @adamfeuerstein]

Another twist...

FDA permits use of Sarepta Therapeutics’ $SRPT Duchenne therapy in younger patients after short-lived halt https://t.co/AAZpW30smm

[Dr. Geraldine, PhD @__GhD_]

The $SRPT rollercoaster is not over. FDA recommended removal of voluntary hold on Elevidys for ambulatory patients and the $SRPT stock shot up ~50% after close, consistent with that trend, it’s up 40% at open.

[Dr. Geraldine, PhD @__GhD_]

$ABVX going from $10 to $69 after reporting positive Phase 3 data that no one believed in is insane. We were obvs bullish and anticipated a >100% increase upon positive data

[Dr. Geraldine, PhD @__GhD_]

Yesterday GHRS stocks were up 85%. Excited to continue watching the story develop as we anticipate an update on the clinical hold, an end of Phase 2 meeting with the FDA, and their Ph3 design.

[Dr. Geraldine, PhD @__GhD_]

Yesterday was a great day in neuropsychiatric drug development with GH Research reporting positive results from the Ph 2 trial evaluating their inhalation formulation of DMT for treatment resistant depression

[Dr. Geraldine, PhD @__GhD_]

Current standard of care JnJ’s SPRAVATO displayed a 4 point reduction in MADRS score while GH001 achieved a placebo adjusted 15 point reduction in MADRS

[Dr. Geraldine, PhD @__GhD_]

Let’s chat about Reviva Pharma

Reviva Pharma is a clinical stage pharmaceutical company developing a serotonin/dopamine modulators in a host of indications with the lead being schizophrenia

[Dr. Geraldine, PhD @__GhD_]

Sometimes good data isn’t all a company needs to be successful.

[Dr. Geraldine, PhD @__GhD_]

@AmdayMed Thanks doc! Appreciate ya!

[Dr. Geraldine, PhD @__GhD_]

Let’s go Amday!!!!

[Amday Wolde, MD @AmdayMed]

Hi #MedTwitter 👋🏾

My name is Amday Wolde! I’m an M4 at @OhioStateMed applying to #Psychiatry for #Match2025

I’m passionate about URiM mentorship (https://t.co/67gP2xON2Y) & addressing SDOH!

Academic interests are cultural & lifestyle psychiatry!

My hobbies include ⚽️🏀👨🏾‍🍳

[Dr. Geraldine, PhD @__GhD_]

Cassava stocks plummet 85%…again, not a surprise considering the inconclusive Phase 2 results which begs the question, why did the FDA let them run a Phase 3?

[Dr. Geraldine, PhD @__GhD_]

A disheartening day for Alzheimer’s disease drug developers with disappointing results coming from both Cassava Sciences and Alector/Abbvie Phase 3 and Phase 2 clinical trials, respectively.

Albeit the Cassava results were expected considering little impact seen in Phase 2

[Dr. Geraldine, PhD @__GhD_]

@AmdayMed It has been! Wishing you the best of luck in your journey to and through residency! I know you’ll be amazing!

[Dr. Geraldine, PhD @__GhD_]

I’m here to talk about science, biotech, biotech stocks (OUTSIDE OF MY COVERAGE) and banter.

[Dr. Geraldine, PhD @__GhD_]

@Beth_Kindig What’s your investment thesis for investing in $NVDA?

[Dr. Geraldine, PhD @__GhD_]

@EthanInvests Oh I completely agree, interested in $MRNA for that exact reason, especially with positive recent data in solid tumors. COVID helped fund the cancer initiatives for sure

[Dr. Geraldine, PhD @__GhD_]

Hi! @EthanInvests

Thoughts on investing in psychedelic therapeutic companies?

[Dr. Geraldine, PhD @__GhD_]

@EthanInvests Also looking at $EDIT myself, haven’t invested yet 🤭

[Dr. Geraldine, PhD @__GhD_]

@EthanInvests Also curious about how vaccine companies (like $MRNA) will take a hit after Trump appoints different folks in office that may not support vaccines

[Dr. Geraldine, PhD @__GhD_]

@EthanInvests Hard to predict since market is heavily dependent on success of clinical trials. A bit easier to follow the data for small/midcap therapeutics companies but more difficult to predict for more service based companies like Ginkgo.